Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Cash & Current Investments (2020 - 2025)

Historic Cash & Current Investments for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to $75.7 million.

  • Barinthus Biotherapeutics' Cash & Current Investments fell 2867.81% to $75.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.7 million, marking a year-over-year decrease of 2867.81%. This contributed to the annual value of $112.4 million for FY2024, which is 2089.52% down from last year.
  • According to the latest figures from Q3 2025, Barinthus Biotherapeutics' Cash & Current Investments is $75.7 million, which was down 2867.81% from $87.8 million recorded in Q2 2025.
  • Barinthus Biotherapeutics' Cash & Current Investments' 5-year high stood at $243.6 million during Q2 2021, with a 5-year trough of $75.7 million in Q3 2025.
  • Moreover, its 5-year median value for Cash & Current Investments was $160.3 million (2023), whereas its average is $159.6 million.
  • In the last 5 years, Barinthus Biotherapeutics' Cash & Current Investments surged by 39473.95% in 2021 and then tumbled by 3381.41% in 2024.
  • Barinthus Biotherapeutics' Cash & Current Investments (Quarter) stood at $214.1 million in 2021, then fell by 9.19% to $194.4 million in 2022, then dropped by 26.9% to $142.1 million in 2023, then dropped by 20.9% to $112.4 million in 2024, then plummeted by 32.67% to $75.7 million in 2025.
  • Its Cash & Current Investments was $75.7 million in Q3 2025, compared to $87.8 million in Q2 2025 and $100.6 million in Q1 2025.